Securities code: Baolingbao Biology Co.Ltd(002286) securities abbreviation: Baolingbao Biology Co.Ltd(002286) Announcement No.: 2022006 Baolingbao Biology Co.Ltd(002286)
Announcement of main business data from January to February 2022
The board of directors and all members of the company guarantee that the contents of the announcement are true, accurate and complete, and there are no false records, misleading statements or major omissions.
1、 Main operating data of the company from January to February 2022
Baolingbao Biology Co.Ltd(002286) (hereinafter referred to as “the company”) had a good start in production and operation from January to February and achieved good business results. According to the preliminary accounting of the company, from January to February 2022, the company achieved an operating revenue of about 401 million yuan, an increase of about 20.89% over the same period last year; The net profit attributable to the shareholders of the listed company was about 26 million yuan, with a loss of 4.1686 million yuan in the same period last year.
2、 Explanatory matters
The above main operating data are the results of the company’s preliminary accounting, which are only used as the reference of investors for phased financial data, and can not be used to calculate the company’s annual performance. Please invest rationally and pay attention to risks. The information disclosure media designated by the company are China Securities News, Shanghai Securities News, securities times, securities daily and cninfo. Com. The information published by the company shall be subject to the announcement published in the above designated newspapers and websites.
It is hereby announced.
Baolingbao Biology Co.Ltd(002286)
Board of directors
March 13, 2022
